GlassScriptPhysician profile
Ann K Chen
NPI 1750358438
$3,155.86
in general payments reported to CMS, 2019-2025
27 companies · $817 in 2025
The $817 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $547 · 2022: $672 · 2023: $605 · 2024: $515 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $712.39 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $515.03 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $362.35 | 2021-2025 | Tremfya, Stelara |
| Ferring Pharmaceuticals INC. | $275.10 | 2021-2024 | Rebyota, Cimzia, Clenpiq |
| Madrigal Pharmaceuticals | $188.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $184.69 | 2023-2025 | |
| Pfizer INC. | $151.29 | 2023-2025 | |
| Boston Scientific Corporation | $144.00 | 2025 | General - Biliary Devices |
| Gilead Sciences, INC. | $86.34 | 2021 | |
| Phathom Pharmaceuticals, INC. | $75.00 | 2024 | Voquezna |
| Amgen INC. | $63.13 | 2023-2025 | Repatha, Repatha, Amjevita |
| Corcept Therapeutics | $41.69 | 2025 | Korlym |
| Merck Sharp & Dohme LLC | $39.22 | 2023 | Verquvo, Belsomra |
| Nestle Healthcare Nutrition INC. | $36.43 | 2022 | |
| Celgene Corporation | $33.63 | 2023 | Zeposia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $30.31 | 2024-2025 | Cologuard Collection Kit |
| Argenx US, INC. | $28.19 | 2023 | Vyvgart |
| Braintree Laboratories, INC. | $27.71 | 2022 | |
| Atricure, INC. | $25.70 | 2022 | |
| Ardelyx, INC. | $23.64 | 2024 | Ibsrela |
| Allergan, INC. | $20.36 | 2021 | |
| Qol Medical, LLC | $18.13 | 2021 | |
| Abbott Laboratories | $16.65 | 2025 | Infinity |
| Regeneron Healthcare Solutions, INC. | $15.78 | 2023 | Dupixent |
| Novo Nordisk INC | $14.83 | 2023 | |
| Sandoz INC. | $13.64 | 2024 | Hyrimoz |
| Takeda Pharmaceuticals U.S.A., INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.